Revisiting pars plana vitrectomy in the primary treatment of diabetic macular edema in the era of pharmacological treatment

Diabetic macular edema (DME) is the most common cause of moderate visual loss in diabetic patients. The current treatment of choice for center-involved DME is anti-vascular endothelial growth factor (VEGF) treatment. Most patients that undergo pharmacological inhibition with anti-VEGF agents need mu...

Descripción completa

Detalles Bibliográficos
Autores principales: Flikier, Stephanie, Wu, Andres, Wu, Lihteh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2019
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947753/
https://www.ncbi.nlm.nih.gov/pubmed/31942427
http://dx.doi.org/10.4103/tjo.tjo_61_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947753/
https://www.ncbi.nlm.nih.gov/pubmed/31942427
http://dx.doi.org/10.4103/tjo.tjo_61_19

Ejemplares similares